Abatacept for GVHD Prophylaxis after Hematopoietic Stem Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Transplant Alliance for Research (STAR) Trial

Sonali Chaudhury(Northwestern University), Monica Bhatia(Columbia University Irving Medical Center), Joe Laskowski(Lurie Children's Hospital), John Horan(Emory University), Jean Sosna(Columbia University), Hemalatha G. Rangarajan(Nationwide Children's Hospital), Gregory M.T. Guilcher(University of Calgary), Chalitha Robinson(Columbia University Irving Medical Center), Ann E. Haight, Allistair Abraham(Children's National)
Transplantation and Cellular Therapy
February 3, 2018
10.1016/j.bbmt.2017.12.674
Cited by 13

Related Papers

The genetic basis and cell of origin of mixed phenotype acute leukaemia
|Nature|2018|383
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
|Journal of Clinical Oncology|2021|255
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248
Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen–Identical Sibling Transplants for Adults With Leukemia
|Journal of Clinical Oncology|2008|204
Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
|Transplantation and Cellular Therapy|2012|201